Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Business Wire•20/10/2026•16:00 ET
0
Key Highlights
- ➤Viridian (VRDN) will report Q3 2026 financial results November 4 before market open
- ➤Management will host an 8:00 a.m. ET conference call and business update
- ➤FDA-approved Lumvoa targets thyroid eye disease treatment
- ➤Elegrobart remains a late-stage investigational subcutaneous therapy for thyroid eye disease
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026.
Get started
Create a free account to read the full story.